Dupont Capital Management Corp Acquires 7,422 Shares of Hologic, Inc. (HOLX)
Dupont Capital Management Corp raised its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 5.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 152,804 shares of the medical equipment provider’s stock after buying an additional 7,422 shares during the period. Dupont Capital Management Corp’s holdings in Hologic were worth $6,934,000 at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. Profund Advisors LLC boosted its stake in shares of Hologic by 7.3% in the first quarter. Profund Advisors LLC now owns 25,861 shares of the medical equipment provider’s stock worth $1,100,000 after buying an additional 1,755 shares during the last quarter. American Capital Management Inc. boosted its stake in shares of Hologic by 0.4% in the first quarter. American Capital Management Inc. now owns 1,158,379 shares of the medical equipment provider’s stock worth $49,289,000 after buying an additional 4,845 shares during the last quarter. Mn Services Vermogensbeheer B.V. boosted its stake in shares of Hologic by 3.5% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 6,678 shares of the medical equipment provider’s stock worth $266,000 after buying an additional 225 shares during the last quarter. Nationwide Fund Advisors boosted its stake in shares of Hologic by 11.2% in the first quarter. Nationwide Fund Advisors now owns 511,970 shares of the medical equipment provider’s stock worth $21,784,000 after buying an additional 51,676 shares during the last quarter. Finally, State of Alaska Department of Revenue acquired a new stake in shares of Hologic during the first quarter worth about $530,000. 94.43% of the stock is owned by institutional investors.
Hologic, Inc. (NASDAQ:HOLX) opened at 38.44 on Tuesday. The stock has a 50 day moving average of $43.51 and a 200-day moving average of $42.93. The company has a market cap of $10.78 billion, a PE ratio of 14.32 and a beta of 0.90. Hologic, Inc. has a 12-month low of $35.15 and a 12-month high of $46.80.
Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.49 by $0.01. The business had revenue of $806.10 million during the quarter, compared to analyst estimates of $799.70 million. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The company’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.51 EPS. On average, equities research analysts anticipate that Hologic, Inc. will post $2.01 earnings per share for the current fiscal year.
A number of brokerages have recently issued reports on HOLX. Stifel Nicolaus boosted their target price on shares of Hologic from $45.00 to $48.00 and gave the company a “buy” rating in a research report on Thursday, May 11th. Jefferies Group LLC reissued a “buy” rating and issued a $49.00 target price on shares of Hologic in a research report on Wednesday, June 28th. Bank of America Corporation reissued a “neutral” rating and issued a $48.00 target price (up previously from $44.00) on shares of Hologic in a research report on Friday, July 21st. Canaccord Genuity reissued a “buy” rating and issued a $53.00 target price on shares of Hologic in a research report on Tuesday, May 9th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $51.00 target price on shares of Hologic in a research report on Friday, July 14th. One research analyst has rated the stock with a sell rating, five have given a hold rating and nine have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $48.64.
In other Hologic news, VP Karleen Marie Oberton sold 4,704 shares of Hologic stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $45.19, for a total transaction of $212,573.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Elaine Ullian sold 8,849 shares of Hologic stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $45.28, for a total value of $400,682.72. Following the transaction, the director now directly owns 23,810 shares of the company’s stock, valued at approximately $1,078,116.80. The disclosure for this sale can be found here. Insiders have sold a total of 60,627 shares of company stock valued at $2,632,911 in the last ninety days. Insiders own 0.79% of the company’s stock.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.